GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (OTCPK:BIOGY) » Definitions » Debt-to-Equity

BioGaia AB (BioGaia AB) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Debt-to-Equity?

BioGaia AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.0 Mil. BioGaia AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.0 Mil. BioGaia AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $208.2 Mil. BioGaia AB's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioGaia AB's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of BioGaia AB was 0.28. The lowest was 0.01. And the median was 0.21.

BIOGY's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

BioGaia AB Debt-to-Equity Historical Data

The historical data trend for BioGaia AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Debt-to-Equity Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.01 - -

BioGaia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioGaia AB's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Debt-to-Equity falls into.



BioGaia AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioGaia AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

BioGaia AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioGaia AB  (OTCPK:BIOGY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


BioGaia AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB (BioGaia AB) Business Description

Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.